Aldeyra's Allergy Drug Misses Endpoint But Company Sees Market Gap
Aldeyra is moving ahead with plans for Phase III trials of its novel allergy drug in the face of a missed Phase IIb endpoint. Its ultimate success could rest on what endpoint the FDA will accept.
You may also be interested in...
The company announced positive results for reproxalap from its Phase III INVIGORATE trial in allergic conjunctivitis, which may be a good sign for its dry eye disease studies.
Market Snapshot: Kala's Phase III nanoparticle along with Aldeyra's aldehyde trap drug and Ocugen's brimonidine/steroid combo, both in Phase II, are among the candidates pursuing Restasis and Xiidra.
Antibiotic incentives, vaccine strategies, drug pricing, patent updates and more hot topics from the Biotechnology Innovation Organization's recent annual conference.